CANF $8.60 Roth ups target to $28. Phase 3 results for dry eye due before the end of the year http://www.streetinsider.com/Analyst+Comments/Can-Fite+BioPharma+%28CANF%29+Target+Raised+to+$28+at+Roth+Capital/9003631.html